Jubilant Life Sciences Ltd said on Tuesday that it expects to deliver stable performance in fourth quarter of 2014-15, buoyed by better operating conditions in contract manufacturing organisation (CMO) business.
The company’s consolidated revenue for the second quarter ended September 30, 2014 was Rs1,371 crore. Revenues from pharmaceuticals was Rs614 crore, and life science ingredients segment was Rs757 crore, up 2% over last year. International revenues, at Rs955 crore, contributed 70% to the overall mix.
Shyam S Bhartia, chairman & managing director and Hari S Bhartia, co-chairman & managing director, Jubilant Life Sciences said in a statement: “The company’s performance in the (second) quarter was affected mainly due to the continued impact of USFDA warning letter on Spokane facility and adverse price impact on account of new capacities and regulatory changes in China in advanced intermediates business. Our radiopharmaceuticals business has started to show the benefits of our strategic initiatives.”